Simao et al.3030 Simão DAS, Teixeira AL, Souza RS, de Paula Lima ED. Evaluation of the Semmes-Weinstein filaments and a questionnaire to assess chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2014;22(10):2767-73.
|
Brazil |
Cross-sectional |
117 |
MSW, QNIA, ECOG |
Hershman et al.3636 Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol. 2013;31(20):2627-33.
|
USA |
Clinical trial |
409 |
FACT-Taxane NTX,NCI - CTC |
Reeves et al.2121 Carlson K, Ocean AJ. Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. Clin Breast Cancer. 2011;11(2):73-81.
|
USA |
Longitudinal |
85 |
EORTC- QLQ-CIPN 20 |
Cavaletti et al.33 Cavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst. 2007;12(3):210-5.
|
Italy |
Longitudinal |
450 |
TNSc, NCI-CTC 2.0 |
Simao et al.2525 Simão DAS, Lima ED, Souza RS, Alves KR, Maia WM. Instrumentos de avaliação da neuropatia periférica induzida por quimioterapia: revisão integrativa e implicações para a prática de enfermagem oncológica. Reme Rev Min Enferm. 2012;16(4):609-15.
|
Brazil |
Review |
- |
ENMG, ECN, TNS, QNIA, FACT/GOG-NTX & PNQ |
Tofthagen, McAllister & McMillanet al.4040 Tofthagen C, McAllister RD, McMillan SC. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clin J Oncol Nurs. 2011;15(2):182-8.
|
USA |
Validation |
167 |
CIPNAT |
Hershman et al.3939 Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat. 2011;125(3):767-74.
|
USA |
Cross-sectional |
50 |
QST, FACT/GOG-NTx |
Cavaletti et al.2626 Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, et al. Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer. 2010;46(3):479-94.
|
Italy |
Review |
- |
NCI-CTC, ECOG, FACT/GOG-NTX, FACT-Taxane, PNS, Oxaliplatin Scale, PNQ, EORTC- QLQ-CIPN 20 |
Wilson et al.2727 Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002;20(7):1767-74.
|
USA |
Clinical trial |
32 |
ECN, EMG |
Loprinzi et al.3333 Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol. 2014;32(10):997-1005.
|
USA |
Clinical trial |
353 |
EORTC- QLQ-CIPN 20, NCI-CTC |
Smith et al.3535 Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359-67.
|
USA |
Clinical trial |
231 |
FACT/GOG-NTX, NCI- CTC |